SPI 339
Alternative Names: NEO 339Latest Information Update: 12 Jan 2024
At a glance
- Originator Spectrum Pharmaceuticals
- Developer Assertio Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Mild cognitive impairment
Most Recent Events
- 02 Jul 2003 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
- 02 Jul 2003 Discontinued - Preclinical for Mild cognitive impairment in USA (unspecified route)
- 02 Jul 2003 SPI 339 is available for licensing (http://www.spectrumpharm.com)